Nautilus Biotech and HanAll Pharmaceutical announce license agreement to develop three Nautilus Biotech products in South Korea

08-Mar-2007

Nautilus Biotech announced the signing of a collaboration and license agreement with HanAll Pharmaceutical to develop and commercialize three Nautilus Biotech products in South Korea: Belerofon® (interferon alpha); Vitatropin® (human growth hormone); and Eporal(TM) (erythropoietin).

The agreement with HanAll Pharmaceuticals is limited to the territory of South Korea; Nautilus Biotech will continue to pursue the clinical development of these products in the USA as part of the Company's strategy for global commercialisation of these products.

Nautilus Biotech's novel technology makes minimal and specific changes to the amino acid sequence in order to slow the breakdown of the protein in the body, in blood, tissues or intestine. The three Nautilus Biotech proprietary proteins included in the agreement have been designed for extended half-life and oral availability. By reducing the number and frequency of treatments needed and offering oral administration, these new drugs will enhance patient convenience and compliance.

The three products that come under the license agreement include Belerofon, Nautilus Biotech's long-lasting human Interferon alpha, which has therapeutic potential for a number of conditions, including chronic Hepatitis C (HCV). Nautilus Biotech submitted an Investigational New Drug (IND) filing for oral Belerofon last month, following its submission in October 2006 for an IND filing for injectable Belerofon. . The license agreement with HanAll Pharmaceutical includes Vitatropin, Nautilus Biotech's proprietary variant of human growth hormone (hGH), for the treatment of children and adults with growth disorders. hGH is currently only available in injectable form and is normally administered daily.

Nautilus Biotech's agreement with HanAll Pharmaceutical also includes the development and commercialisation in South Korea of Eporal, an orally available version of the hormone erythropoietin, which stimulates the body to produce more red blood cells and is used in the treatment of anaemia.

https://www.bionity.com/en/news/62495/nautilus-biotech-and-hanall-pharmaceutical-announce-license-agreement-to-develop-three-nautilus-biotech-products-in-south-korea.html